This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Good morning everyone and welcome to the precession of the third day of the Morgan Stanley 2012 Global Healthcare Conference. I am Marshall Urist one of the biotech analysts here at Morgan Stanley and before we get started just a couple of quick pieces of business. Number one, any of – all of our relevant research disclosures can be found in our website or on any piece of our research and second, it is absolutely supposed to be an open and interactive session so if you have questions please raise your hand and there are certainly microphones circulating. So, with that we are happy to be here this morning with Dan Junius, President and CEO of ImmunoGen. Dan, thanks for being with us this morning and maybe to start off take a few minutes to give sort of an overview of what you are focused on right now and what are the most kind of important things for people to think about in the next 12 months.
Sure. Thanks Marshall and thank you for inviting us. Maybe just by the way of background in terms of the company, the technology, and our movement is some of the things that we are involved with. The company is built on a technology that uses the targeting ability of an antibody to find a target on a cancer cell and we’ve developed a technology that has both proprietary toxin that we use and a means of attaching that toxin to the antibody that is delivered for us a very effective targeted therapy for oncology.